NAFLD/NASH PhaseII Clinical Study Recruits 1st Patient
Sydney, Sep 14, 2022 AEST (ABN Newswire) - VGI Health Technology Limited (
NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has made significant progress in its Phase II clinical study in Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic SteatoHepatitis (NASH).
Research Governance Office approvals have been received from the Fiona Stanley Hospital in Western Australia, the Concord Repatriation General Hospital and the John Hunter Hospital in New South Wales and these sites have been added as clinical study sites along with the existing sites The Gallipoli Medical Research Foundation (GMRF) in Queensland and The Royal Melbourne Hospital in Victoria.
The study will enrol eighty NAFLD/NASH patients across eight sites in Australia and these five sites have commenced recruitment of patients.
This study will be a randomised, double-blind, placebo-controlled Phase II clinical study on NAFLD/NASH to analyse the efficacy and safety of IVB001, a drug candidate based on the noninvasive and direct delivery of tocotrienols using Invictus' patented transmucosal delivery platform.
Professor Darrell Crawford, the Director of Research for the GMRF and a Member of the Invictus Scientific Advisory Board, said "We are very excited that the first patient for this Phase II clinical study in NAFLD/NASH has now been recruited and this patient is expected to commence dosing on 5 October 2022."
About VGI Health Technology Limited
VGI Health Technology Limited (NSX:VTL) is an Australian public listed biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.
| ||
|
